{"id":"7ceffb49f695","type":"article","url":"https://hartvaat.nl/2019/11/01/themis-en-themis-pci-editorial-perspectief/","title":"THEMIS en THEMIS-PCI: editorial perspectief","title_en":"THEMIS and THEMIS-PCI.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehz707","source_url":"https://doi.org/10.1093/eurheartj/ehz707","authors":["Deepak L Bhatt","Philippe Gabriel Steg"],"significance":5,"published":"2019-11-01","source_date":"2019-11-01","image":"","kennis":[],"congress":"","summary_en":"This European Heart Journal editorial discussed the THEMIS and THEMIS-PCI trial results with ticagrelor in stable coronary disease and diabetes, evaluating the narrow risk-benefit balance of intensified antiplatelet therapy.","created":"2026-07-03T10:28:14Z","updated":"2026-07-03T13:27:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Editorial in European Heart Journal over de THEMIS- en THEMIS-PCI-trials met ticagrelor bij stabiel coronairlijden en diabetes.","abstract_original":""}